India Strives for ‘Aatmanirbharta’ in Medicine: Progress and Pitfalls in Reducing China’s API Grip

NEW DELHI — In the heart of India’s pharmaceutical hubs, a quiet revolution is taking place, one aimed at securing the nation’s health from the whims of global supply chains. For decades, India has been dubbed the “Pharmacy of the World,” yet this title has long been shadowed by a precarious reality: a staggering 70% to 100% dependence on China for the raw materials needed to make essential medicines.

New data released by the Ministry of Chemicals and Fertilizers on March 10, 2026, reveals both the depth of this challenge and the significant strides made toward self-reliance. While 2025 ended with nearly 56,800 metric tonnes of domestic manufacturing capacity established for critical drugs, many life-saving antibiotics and vitamins still remain almost entirely tethered to Chinese imports.

The Dependency Map: A Tale of Two Annexures

The government’s latest report, placed before the Parliament, highlights a persistent “high-dependence” on China for Active Pharmaceutical Ingredients (APIs)—the biologically active components in drugs that produce the intended health effects.

According to Annexure-I of the report, for the fiscal years 2023-24 and 2024-25, several critical APIs saw 100% import reliance on China. These include:

• Rifa S Sodium: Used in treating tuberculosis.

• Methyl Dopa: An essential medication for high blood pressure during pregnancy.

• Sulphadimidine: A broad-spectrum antibiotic.

Other essential medicines like Norfloxacin, Gentamycin, and Vitamin B12 maintain a dependency rate hovering between 90% and 99%.

“This isn’t just an economic issue; it’s a public health security risk,” says Dr. Aranya Sharma, a supply chain analyst and former consultant for the World Health Organization (WHO), who was not involved in the government report. “If a single geopolitical event or another pandemic shuts down these specific trade routes, the production of basic antibiotics and blood pressure meds in India could grind to a halt within weeks.”

The PLI Response: Building a Fortress at Home

To counter this, the Indian government launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in 2020. The objective was simple: pay companies to manufacture these critical materials on Indian soil.

The March 2026 update shows the strategy is yielding tangible results:

• Capacity Created: 38 greenfield projects have been commissioned as of December 2025.

• Investment Surge: While the industry committed ₹4,329.95 crore, the actual investment has exceeded expectations, reaching ₹4,814.1 crore.

• Import Substitution: The scheme has already facilitated the avoidance of imports worth ₹2,192.04 crore.

Under the PLI umbrella, domestic production has begun for 28 out of 41 identified “critical” products. These include foundational chemicals for antibiotics like Penicillin G and 7-ACA, which were previously almost entirely imported.

Public Health Implications: What This Means for Patients

For the average consumer, API independence translates directly to drug security and price stability. During the COVID-19 pandemic, the cost of Paracetamol and certain antibiotics spiked by over 100% due to Chinese supply disruptions. By manufacturing these at home, India can buffer its citizens against such volatile price swings.

Furthermore, domestic manufacturing allows for stricter oversight by the Central Drugs Standard Control Organisation (CDSCO). “Localizing the supply chain means we have more ‘eyes on the floor’ regarding quality control from the very first chemical reaction, not just the final tablet,” explains Rajat Mittal, a pharmaceutical manufacturing expert.

The Roadblocks: Why Total Independence is Elusive

Despite the optimism, the transition is not without friction. Critics and industry insiders point out that China’s manufacturing scale remains an “economic Goliath.”

“The PLI scheme is a fantastic start, but we must acknowledge the cost gap,” says Dr. Sharma. “Chinese manufacturers often benefit from massive state subsidies and established infrastructure that allows them to price APIs lower than the cost of production in a brand-new Indian facility. Without sustained government support, private players may find it hard to compete once the initial PLI incentives expire.”

Furthermore, while India is making progress on APIs, it still relies on China for “Key Starting Materials” (KSMs)—the even more basic chemicals used to build APIs. True independence requires moving even further back in the supply chain, a process known as backward integration.

Looking Ahead: The 2026 Horizon

As of December 2025, the government has disbursed ₹54.81 crore in incentives, a figure expected to rise sharply as more plants reach full operational scale. The focus is now shifting toward the completion of Bulk Drug Parks in Andhra Pradesh, Gujarat, and Himachal Pradesh. These parks aim to provide “plug-and-play” infrastructure, including common effluent treatment plants, to further drive down the cost of manufacturing for private companies.

For the healthcare professional, these developments signal a more resilient prescription environment. For the consumer, it offers the promise that the medicine in their cabinet won’t be held hostage by global logistics.

As India enters the 2026-27 fiscal year, the goal of “Aatmanirbharta” (self-reliance) in pharmaceuticals is no longer just a policy slogan—it is a multi-billion rupee infrastructure reality, albeit one that is still being tested against the relentless efficiency of the global market.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Government Source: Press Information Bureau (PIB) Delhi. “APIs Imports from China.” Posted 10 MAR 2026. [PRID: 2237414].

Annexure-II